Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Other Working Capital Changes: 2019-2025

Historic Other Working Capital Changes for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to $122,000.

  • Eton Pharmaceuticals' Other Working Capital Changes fell 23.27% to $122,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year increase of 513.64%. This contributed to the annual value of $3.3 million for FY2024, which is 3662.77% up from last year.
  • Per Eton Pharmaceuticals' latest filing, its Other Working Capital Changes stood at $122,000 for Q3 2025, which was down 94.70% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Other Working Capital Changes ranged from a high of $3.5 million in Q4 2024 and a low of -$3.0 million during Q1 2025.
  • Its 3-year average for Other Working Capital Changes is $245,909, with a median of -$79,000 in 2024.
  • In the last 5 years, Eton Pharmaceuticals' Other Working Capital Changes spiked by 1,400.00% in 2021 and then tumbled by 3,663.29% in 2025.
  • Quarterly analysis of 5 years shows Eton Pharmaceuticals' Other Working Capital Changes stood at $743,000 in 2021, then tumbled by 61.10% to $289,000 in 2022, then skyrocketed by 126.64% to $655,000 in 2023, then soared by 437.40% to $3.5 million in 2024, then decreased by 23.27% to $122,000 in 2025.
  • Its Other Working Capital Changes stands at $122,000 for Q3 2025, versus $2.3 million for Q2 2025 and -$3.0 million for Q1 2025.